Table 2.
Core basal markers | Triple-negative tumors (N = 266) | Percentage (%) |
---|---|---|
CK5/6 | 172 | 64.6 |
CK14 | 117 | 43.9 |
CK17 | 138 | 51.8 |
CK 5/6 and CK14 | 106 | 39.8 |
CK 5/6 and CK17 | 122 | 45.8 |
CK 5/6, EGFR, CK14 and/or CK17 | 200 | 75.2 |
CK: cytokeratin.
Core basal markers | Triple-negative tumors (N = 266) | Percentage (%) |
---|---|---|
CK5/6 | 172 | 64.6 |
CK14 | 117 | 43.9 |
CK17 | 138 | 51.8 |
CK 5/6 and CK14 | 106 | 39.8 |
CK 5/6 and CK17 | 122 | 45.8 |
CK 5/6, EGFR, CK14 and/or CK17 | 200 | 75.2 |
CK: cytokeratin.